NCT02744248View on ClinicalTrials.gov

Phase I , MTD, Pharmacokinetic, Safety/Tolerability, Efficacy of IOP Injection for MRI in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2017

Conditions
Magnetic Resonance Imaging
Interventions
DRUG

IOP Injection

IOP Injection 20 mg Fe/ml, intravenous injection

DRUG

0.9% normal saline

0.9% normal saline 10 ml, intravenous injection

Trial Locations (1)

112

Taipei Veterans General Hospital, Taipei

All Listed Sponsors
lead

MegaPro Biomedical Co. Ltd.

INDUSTRY

NCT02744248 - Phase I , MTD, Pharmacokinetic, Safety/Tolerability, Efficacy of IOP Injection for MRI in Healthy Subjects | Biotech Hunter | Biotech Hunter